DE60136916D1 - Zusammensetzung und verfahren zur verhütung und/oder behandlung von der pii allergien - Google Patents

Zusammensetzung und verfahren zur verhütung und/oder behandlung von der pii allergien

Info

Publication number
DE60136916D1
DE60136916D1 DE60136916T DE60136916T DE60136916D1 DE 60136916 D1 DE60136916 D1 DE 60136916D1 DE 60136916 T DE60136916 T DE 60136916T DE 60136916 T DE60136916 T DE 60136916T DE 60136916 D1 DE60136916 D1 DE 60136916D1
Authority
DE
Germany
Prior art keywords
allergen
patient
towards
pii
allergies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60136916T
Other languages
English (en)
Inventor
Jean-Marie Saint-Remy
Marc Jacquemin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Sciences Research Partners vzw
Original Assignee
Life Sciences Research Partners vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Sciences Research Partners vzw filed Critical Life Sciences Research Partners vzw
Application granted granted Critical
Publication of DE60136916D1 publication Critical patent/DE60136916D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60136916T 2000-03-17 2001-03-16 Zusammensetzung und verfahren zur verhütung und/oder behandlung von der pii allergien Expired - Fee Related DE60136916D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0006437.8A GB0006437D0 (en) 2000-03-17 2000-03-17 Compounds for the modulation of allergen sensitivity by antigens sharing T cell epitopes with allergens
PCT/BE2001/000046 WO2001070263A1 (en) 2000-03-17 2001-03-16 Composition and method for the prevention and/or the treatment of allergy

Publications (1)

Publication Number Publication Date
DE60136916D1 true DE60136916D1 (de) 2009-01-22

Family

ID=9887805

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60136916T Expired - Fee Related DE60136916D1 (de) 2000-03-17 2001-03-16 Zusammensetzung und verfahren zur verhütung und/oder behandlung von der pii allergien

Country Status (9)

Country Link
US (1) US7595052B2 (de)
EP (1) EP1267921B1 (de)
JP (1) JP2003527438A (de)
AT (1) ATE416787T1 (de)
AU (2) AU2001243964B9 (de)
CA (1) CA2402636A1 (de)
DE (1) DE60136916D1 (de)
GB (1) GB0006437D0 (de)
WO (1) WO2001070263A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657480T3 (es) * 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
ES2650236T3 (es) 2008-02-14 2018-01-17 Life Sciences Research Partners Vzw Linfocitos T CD4+ con propiedades citolíticas
ES2545885T3 (es) * 2008-02-14 2015-09-16 Life Sciences Research Partners Vzw Eliminación de respuestas inmunitarias contra vectores virales
AU2009214039B2 (en) * 2008-02-14 2013-09-19 Katholieke Universiteit Leuven Immunogenic control of tumours and tumour cells
CA2724440C (en) * 2008-02-14 2018-01-09 Life Sciences Research Partners Vzw Strategies to prevent and/or treat immune responses to soluble allofactors
CA2715611C (en) 2008-02-14 2018-03-13 Life Sciences Research Partners Vzw Immunotherapy targeting intracellular pathogens
CA2715517C (en) 2008-02-14 2018-07-24 Life Sciences Research Partners Vzw Immunogenic peptides and their use in preventing or treating allograft rejection
US20120141502A1 (en) * 2009-04-20 2012-06-07 Eric Dixon Antibodies specific to e6 proteins of hpv and use thereof
PT2643345T (pt) 2010-11-25 2021-04-14 Imnate Sarl Péptidos imunogénicos para utilizar na prevenção e/ou no tratamento de doenças infecciosas, doenças autoimunes, respostas imunitárias a alofatores, doenças alérgicas, tumores, rejeição de enxertos e respostas imunitárias contra vetores virais usados para a terapêutica de genes ou na vacinação genética
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
CA2995771A1 (en) 2015-09-25 2017-03-30 Imcyse Sa Improved methods and compounds for eliminating immune responses to therapeutic agents
KR20220132023A (ko) 2016-04-19 2022-09-29 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090386A (en) * 1991-07-12 2000-07-18 Griffith; Irwin J. T cell peptides of the CRX JII allergen
WO1993008279A1 (en) 1991-10-16 1993-04-29 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
AUPM307793A0 (en) * 1993-12-22 1994-01-20 Holt, Patrick G Professor Prophylaxis of allergic disease
JPH10259198A (ja) * 1996-12-24 1998-09-29 Sankyo Co Ltd 連結したｔ細胞エピトープとその用途
AU743647B2 (en) 1998-01-31 2002-01-31 Mt. Sinai School Of Medicine Of New York University Methods and reagents for decreasing allergic reactions
WO2000050044A1 (en) 1999-02-25 2000-08-31 Tai June Yoo Vaccine for house dust mite allergen using naked plasmid dna

Also Published As

Publication number Publication date
AU2001243964B9 (en) 2005-03-17
EP1267921B1 (de) 2008-12-10
WO2001070263A1 (en) 2001-09-27
GB0006437D0 (en) 2000-05-10
EP1267921A1 (de) 2003-01-02
JP2003527438A (ja) 2003-09-16
US20030129205A1 (en) 2003-07-10
CA2402636A1 (en) 2001-09-27
US7595052B2 (en) 2009-09-29
AU4396401A (en) 2001-10-03
ATE416787T1 (de) 2008-12-15
AU2001243964B2 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
DE60136916D1 (de) Zusammensetzung und verfahren zur verhütung und/oder behandlung von der pii allergien
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
DE60221665D1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE438405T1 (de) Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes
DE69915310D1 (de) Methoden zur behandlung der salzabhängigen hypertonie
DE69429101D1 (de) Verbindungen und zusammensetzungen zur behandlung von allergien und entzündungen
DE60219658D1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
DE60042941D1 (de) Verwendung von anti-cd3 monoklonale antikörper und il-5 zur behandlung von autoimmunkrankheiten
DE69423533D1 (de) Zubereitungen zur Behandlung von Impotenz, die ein Alpha-1 inhibitor und ein Alpha-2 inhibitor enthalten
ATE283920T1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
DE60231475D1 (de) Materialien und methoden zur behandlung von hepatitis c
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
ATE338566T1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
ATE401912T1 (de) Methoden der zubereitung von immunglobulin und dessen verwendungen
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE540695T1 (de) Verfahren zur modulation von il-13
ATE235249T1 (de) Die von morphogenen peptiden hervorgerufene wiederherstellung von gewebe aus sinneszellen
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE419348T1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE60118363D1 (de) Methoden zur behandlung des kryptorchysmus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee